SCHEMBL7659626

SCHEMBL7659626

CC(=O)On1c(=O)c(-c2cn(CCN)c3ccccc23)nc2cc3ccccc3cc21

nearest known ligand 0.44

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CAMK2D Q13557 12/20 0.43
KDR P35968 2/20 0.42
GSK3B P49841 2/20 0.42
FLT3 P36888 1/20 0.42
USP2 O75604 1/20 0.42
ALDH1A1 P00352 1/20 0.42
CYP1A2 P05177 1/20 0.42
CYP3A4 P08684 1/20 0.42
CYP2C9 P11712 1/20 0.42
CYP2C19 P33261 1/20 0.42
CLK4 Q9HAZ1 1/20 0.42
PIM1 P11309 1/20 0.40
ASH1L Q9NR48 1/20 0.39
PRKCB P05771 1/20 0.38
PRKCA P17252 1/20 0.38
PRKCH P24723 1/20 0.38
PRKCQ Q04759 1/20 0.38
PRKCD Q05655 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7664768 0.94 CAMK2D (0.46) CAMK2DKDRGSK3BPIM1
SCHEMBL7654522 0.87 ALDH1A1 (0.42) ALDH1A1PRKCBPRKCAPRKCHPRKCQ
SCHEMBL7658933 0.86 PDE4B (0.46) CAMK2DKDRGSK3B
SCHEMBL7657926 0.86 USP2 (0.41) USP2ALDH1A1CYP1A2CYP3A4CYP2C9
SCHEMBL7662878 0.86 ACKR3 (0.36) CAMK2DUSP2ALDH1A1CYP1A2CYP3A4
SCHEMBL7656438 0.85 CAMK2D (0.42) CAMK2DKDRGSK3BPIM1
SCHEMBL7662107 0.84 CAMK2D (0.45) CAMK2DKDRGSK3BUSP2ALDH1A1
SCHEMBL7655234 0.84 CAMK2D (0.40) CAMK2DKDRGSK3BUSP2ALDH1A1
SCHEMBL7665495 0.83 CAMK2D (0.41) CAMK2DKDRGSK3BPIM1
SCHEMBL7664149 0.83 CAMK2D (0.41) CAMK2DKDRGSK3BPIM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1071683-A1 NEW COMPOUNDS AstraZeneca AB (SE) 2001-01-31 EP claimed
WO-1999046264-A1 NEW COMPOUNDS ASTRAZENECA AB (SE) 1999-09-16 WO claimed
US-6458792-B1 MEDICAMENT FOR THE TREATMENT OF INFLAMMATORY, IMMUNOLOGICAL, BRONCHOPULMONARY, CARDIOVASCULAR, ONCOLOGICAL OR CNS-DEGENERATIVE DISORDERS. ASTRAZENECA AB (SE) 2002-10-01 US disclosed
EP-1071683-A1 NEW COMPOUNDS AstraZeneca AB (SE) 2001-01-31 EP disclosed
WO-1999046264-A1 NEW COMPOUNDS ASTRAZENECA AB (SE) 1999-09-16 WO disclosed